4.5 Article

Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax

Journal

VACCINE
Volume 29, Issue 26, Pages 4308-4315

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.04.028

Keywords

Malaria; Plasmodium vivax; Pvs230; Gametocyte surface antigen; Purifying selection; Transmission-blocking vaccine

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology [18073013, 18GS03140013, 20390120, 19406009, 21022034, 22406012]
  2. Ministry of Health, Labour, and Welfare, Japan [H20-Shinkou-ippan-013, H21-Chikyukibo-ippan-005]
  3. Japan Society for the Promotion of Science
  4. National Institutes of Health of USA [RO1 AI 075416-01]
  5. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [470570/2006-7]
  6. Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP) [05/51988-0, 07/51199-0]
  7. National Natural Science Foundation of China [30972774]
  8. Grants-in-Aid for Scientific Research [23406007, 20390120, 19406009, 22406012, 23590498] Funding Source: KAKEN

Ask authors/readers for more resources

Pfs230, surface protein of gametocyte/gamete of the human malaria parasite, Plasmodium falciparum, is a prime candidate of malaria transmission-blocking vaccine. Plasmodium vivax has an ortholog of Pfs230 (Pvs230), however, there has been no study in any aspects on Pvs230 to date. To investigate whether Pvs230 can be a vivax malaria transmission-blocking vaccine, we performed evolutionary and population genetic analysis of the Pvs230 gene (pvs230: PVX_003905). Our analysis of Pvs230 and its orthologs in eight Plasmodium species revealed two distinctive parts: an interspecies variable part (IVP) containing species-specific oligopeptide repeats at the N-terminus and a 7.5 kb interspecies conserved part (ICP) containing 14 cysteine-rich domains. Pvs230 was closely related to its orthologs, Pks230 and Pcys230, in monkey malaria parasites. Analysis of 113 pvs230 sequences obtained from worldwide, showed that nucleotide diversity is remarkably low in the non-repeat 8-kb region of pvs230 (theta pi = 0.00118) with 77 polymorphic nucleotide sites, 40 of which results in amino acid replacements. A signature of purifying selection but not of balancing selection was seen on pvs230. Functional and/or structural constraints may limit the level of polymorphism in pvs230. The observed limited polymorphism in pvs230 should ground for utilization of Pvs230 as an effective transmission-blocking vaccine. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available